keyword
MENU ▼
Read by QxMD icon Read
search

HBsAg Clearance

keyword
https://www.readbyqxmd.com/read/28903779/hepatitis-delta-virological-and-clinical-aspects
#1
REVIEW
Luan Felipo Botelho-Souza, Mariana Pinheiro Alves Vasconcelos, Alcione de Oliveira Dos Santos, Juan Miguel Villalobos Salcedo, Deusilene Souza Vieira
There are an estimated 400 million chronic carriers of HBV worldwide; between 15 and 20 million have serological evidence of exposure to HDV. Traditionally, regions with high rates of endemicity are central and northern Africa, the Amazon Basin, eastern Europe and the Mediterranean, the Middle East and parts of Asia. There are two types of HDV/HBV infection which are differentiated by the previous status infection by HBV for the individual. Individuals with acute HBV infection contaminated by HDV is an HDV/HBV co-infection, while individuals with chronic HBV infection contaminated by HDV represent an HDV/HBV super-infection...
September 13, 2017: Virology Journal
https://www.readbyqxmd.com/read/28875955/efficacy-of-real-world-entecavir-therapy-in-treatment-na%C3%A3-ve-chronic-hepatitis-b-patients
#2
Yan-Di Xie, Hui Ma, Bo Feng, Lai Wei
Background: Entecavir (ETV) has been shown to be effective in randomized controlled trials in highly selected patients with hepatitis B virus (HBV) infection. This study aimed to evaluate the efficacy of ETV in chronic hepatitis B (CHB) patients in the real-world setting. Methods: A total of 233 treatment-naïve, CHB patients who received at least 12 months of ETV treatment were included in this retrospective study. Rates of virological response (VR), hepatitis B s antigen (HBsAg) loss, hepatitis B e antigen (HBeAg) clearance/seroconversion, virological breakthrough, cirrhosis, and hepatocellular carcinoma were evaluated...
September 20, 2017: Chinese Medical Journal
https://www.readbyqxmd.com/read/28869890/development-of-anti-hepatitis-b-surface-hbs-antibodies-after-hbs-antigen-loss-in-hiv-hepatitis-b-virus-co-infected-patients
#3
Anders Boyd, Laetitia Canini, Joël Gozlan, Caroline Lascoux-Combe, Patrick Miailhes, Laurent Fonquernie, Pierre-Marie Girard, Karine Lacombe
BACKGROUND: Hepatitis B surface antigen (HBsAg)-seroconversion, or loss of HBsAg and acquisition of anti-hepatitis B surface (HBs) antibodies, defines functional cure of chronic hepatitis B virus (HBV) infection. After HBsAg-loss, little is known regarding the development of anti-HBs antibodies and even less so in individuals co-infected with HIV. OBJECTIVES: To determine anti-HBs antibody kinetics after HBsAg-loss and explore determinants of HBsAg-seroconversion in HIV-HBV co-infected patients...
August 25, 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/28856289/recommendations-for-the-treatment-of-hepatitis-b-in-2017
#4
REVIEW
Robert Flisiak, Waldemar Halota, Jerzy Jaroszewicz, Jacek Juszczyk, Piotr Małkowski, Małgorzata Pawłowska, Anna Piekarska, Krzysztof Simon, Krzysztof Tomasiewicz, Marta Wawrzynowicz-Syczewska
The therapeutic goal which is currently unfrequent but realistic in HBV infected patients is sustained HBsAg clearance. It is preceded by the loss or significant suppression of HBV replication and leads to inhibition of the progression of liver fibrosis, normalization of biochemical indicators of liver damage, reduction in the risk of hepatocellular carcinoma, prolongation of survival, prevention of HBV infection in the transplanted organ in post-transplant patients, enhancement of the quality of life, inhibition or reversal of extrahepatic changes associated with HBV infection, and halting of the spread of HBV infections...
June 2017: Clin Exp Hepatol
https://www.readbyqxmd.com/read/28822954/the-variability-of-hepatitis-b-envelope-is-associated-with-hbs-antigen-persistence-in-either-chronic-or-acute-hbv-genotype-a-infection
#5
Marine Eschlimann, Brice Malvé, Aurélie Velay, Honorine Fenaux, Sibel Berger, Jean-Pol Frippiat, Fabien Zoulim, Mouni Bensenane, Jean-Pierre Bronowicki, François Goehringer, Thierry May, Hélène Jeulin, Evelyne Schvoerer
BACKGROUND: More than 240 million people are chronically infected by hepatitis B virus (HBV) worldwide. Envelope proteins play a crucial role in viral cellular entry and immune recognition. The loss of HBs antigen (HBsAg) correlated with a good clinical prognosis is rarely achieved with or without treatment (3-16%). OBJECTIVES: HBV envelope variability was investigated according to HBsAg persistence. STUDY DESIGN: The cohort consisted of 15 HBV genotype A-infected patients divided into "resolvers", with HBsAg clearance, and "non-resolvers", with HBsAg persistence and in subgroups: acute (n=5, AHBV) or chronic infection (n=4, CHBV) and HBV/HIV coinfection (n=6, CHBV/HIV)...
August 5, 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/28802168/impact-of-hepatitis-b-vaccination-on-hbsag-kinetics-interferon-inducible-protein-10-level-and-recurrence-of-viremia
#6
Amr Shaaban Hanafy
BACKGROUND AND AIMS: Persistent HBs antigenemia >1000IU/ml has a possibility of viral reactivation and HCC in 8%, so we investigated the effect of HBV vaccine on HBsAg, IP-10, and recurrence of viremia. METHODS: Group I: inactive carriers(n=100). Group II: CHB exposed to nucleos(t)ides (n=120) till 1year after HBe seroconversion and HBV DNA disappearance in HBeAg positive (n=60) or3years after DNA disappearance in HBeAg negativepatients (n=60). All showed persistent HBs antigenemia...
August 9, 2017: Cytokine
https://www.readbyqxmd.com/read/28792701/predictive-value-of-hepatitis-b-core-related-antigen-hbcrag-during-the-natural-history-of-hepatitis-b-virus-infection
#7
Yu Gou, Yanhua Zhao, Chenli Rao, Shu Feng, Tingting Wang, Dongdong Li, Chuanmin Tao
BACKGROUND: The natural history of HBV infection includes immune tolerance (IT), immune clearance (IC), HBeAg-negative inactive/quiescent carrier (ENQ), and HBeAg-negative hepatitis (ENH) phases. As the current biomarkers for discriminating the four phases still have some weaknesses, additional serological indicators are needed. Hepatitis B core-related antigen (HBcrAg) encoded with the precore/core gene contains denatured HBeAg, HBV core antigen (HBcAg), and a 22-KDa precore protein (p22cr) and has been demonstrated to have a close association with the natural history of hepatitis B infection...
July 1, 2017: Clinical Laboratory
https://www.readbyqxmd.com/read/28750917/predictive-role-of-serum-hbsag-and-hbcrag-kinetics-in-patients-with-hbeag-negative-chronic-hepatitis-b-receiving-pegylated-interferon-based-therapy
#8
Natthaya Chuaypen, Nawarat Posuwan, Salyavit Chittmittraprap, Nattiya Hirankarn, Sombat Treeprasertsuk, Yasuhito Tanaka, Noboru Shinkai, Yong Poovorawan, Pisit Tangkijvanich
OBJECTIVES: To investigate the role of serum hepatitis B core-related antigen (HBcrAg) kinetics in predicting long-term outcome of pegylated interferon (PEG-IFN)-based therapy in patients with HBeAg-negative chronic hepatitis B (CHB). METHODS: 121 Thai patients with HBeAg-negative CHB recruited from a previous randomized trial of 48-week PEG-IFN alone or combined with entecavir were enrolled. HBsAg and HBcrAg levels were serially examined. Paired biopsies at baseline and post-treatment were assessed for intrahepatic cccDNA...
July 24, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28738454/-development-of-markov-models-for-economics-evaluation-of-strategies-on-hepatitis-b-vaccination-and-population-based-antiviral-treatment-in-china
#9
P C Yang, S X Zhang, P P Sun, Y L Cai, Y Lin, Y H Zou
Objective: To construct the Markov models to reflect the reality of prevention and treatment interventions against hepatitis B virus (HBV) infection, simulate the natural history of HBV infection in different age groups and provide evidence for the economics evaluations of hepatitis B vaccination and population-based antiviral treatment in China. Methods: According to the theory and techniques of Markov chain, the Markov models of Chinese HBV epidemic were developed based on the national data and related literature both at home and abroad, including the settings of Markov model states, allowable transitions and initial and transition probabilities...
July 10, 2017: Zhonghua Liu Xing Bing Xue za Zhi, Zhonghua Liuxingbingxue Zazhi
https://www.readbyqxmd.com/read/28732143/ifnl4-rs368234815-and-rs117648444-variants-predict-off-treatment-hbsag-seroclearance-in-ifn-treated-hbeag-negative-chronic-hepatitis-b-patients
#10
Enrico Galmozzi, Floriana Facchetti, Glenda Grossi, Alessandro Loglio, Mauro Viganò, Giovanna Lunghi, Massimo Colombo, Pietro Lampertico
BACKGROUND & AIM: Robust baseline predictors of interferon (IFN) response in HBeAg-negative chronic hepatitis B (CHB) patients are not currently available. The recently described rs368234815 TT/ΔG dinucleotide and rs117648444 nonsynonymous P70S polymorphisms in IFN lambda 4 (IFNL4) gene, which are strongly associated with response to IFN in hepatitis C virus (HCV) infection, could be also useful in IFN-treated CHB patients. Here we assessed whether IFNL4 rs368234815 and rs117648444 polymorphisms predict IFN-induced HBsAg clearance in CHB patients...
July 21, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28699816/enrichment-of-ly6c-hi-monocytes-by-multiple-gm-csf-injections-with-hbv-vaccine-contributes-to-viral-clearance-in-a-hbv-mouse-model
#11
Weidong Zhao, Xian Zhou, Gan Zhao, Qing Lin, Xianzheng Wang, Xueping Yu, Bin Wang
Adjuvants are considered a necessary component for HBV therapeutic vaccines but few are licensed in clinical practice due to concerns about safety or efficiency. In our recent study, we established that a combination protocol of 3-day pretreatments with GM-CSF before a vaccination (3 × GM-CSF+VACCINE) into the same injection site could break immune tolerance and cause over 90% reduction of HBsAg level in the HBsAg transgenic mouse model. Herein, we further investigated the therapeutic potential of the combination in AAV8-1...
July 12, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28648686/circulating-micrornas-as-potential-biomarkers-of-hbv-infection-persistence
#12
Jie Chen, Xiaojuan Wu, Bei Cai, Zhenzhen Su, Lixin Li, Yunfei An, Lanlan Wang
OBJECTIVES: To investigate different microRNA (miRNA) expression profile in patients of hepatitis B virus (HBV) infection compared with virus spontaneous clearance ones, and try to find new biomarker for diagnosis and treatment assessment. METHODS: miRNA expression profiling was analyzed in patients with HBV infection and patients with virus spontaneous clearance by Affymetrix Gene Chip miRNA 4.0 Arrays. The differently expressed miRNAs, as verified by RT-PCR, were analyzed and compared with each other in the two groups of patients...
June 23, 2017: Infection, Genetics and Evolution
https://www.readbyqxmd.com/read/28623307/both-interferon-alpha-and-lambda-can-reduce-all-intrahepatic-hdv-infection-markers-in-hbv-hdv-infected-humanized-mice
#13
Katja Giersch, Maria Homs, Tassilo Volz, Martina Helbig, Lena Allweiss, Ansgar W Lohse, Jörg Petersen, Maria Buti, Teresa Pollicino, Camille Sureau, Maura Dandri, Marc Lütgehetmann
Co-infection with hepatitis B (HBV) and D virus (HDV) is associated with the most severe course of liver disease. Interferon represents the only treatment currently approved. However, knowledge about the impact of interferons on HDV in human hepatocytes is scant. Aim was to assess the effect of pegylated interferon alpha (peg-IFNα) and lambda (peg-IFNλ), compared to the HBV-polymerase inhibitor entecavir (ETV) on all HDV infection markers using human liver chimeric mice and novel HDV strand-specific qRT-PCR and RNA in situ hybridization assays, which enable intrahepatic detection of HDV RNA species...
June 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28611343/hbsag-clearance-in-chronic-hepatitis-b-patients-with-add-on-pegylated-interferon-alfa-2a-to-ongoing-tenofovir-treatment-a-randomized-controlled-study
#14
Hamad Al Ashgar, Musthafa C Peedikayil, Mohammed Al Quaiz, Fahad Al Sohaibani, Abdulrahman Al Fadda, Mohammed Q Khan, Einar Thoralsson, Sahar Al Thawadi, Ahmed Al Jedai, Khalid Al Kahtani
BACKGROUND/AIMS: The ideal end point of treatment for chronic hepatitis B virus (HBV) infection is sustained off-therapy hepatitis B surface antigen (HBsAg) loss with or even without seroconversion to anti-HBs. We investigated the role of adding PEGylated interferon (PEG IFN) to ongoing tenofovir treatment in chronic HBV patients for achieving HBsAg clearance. PATIENTS AND METHODS: In this randomized controlled trial, chronic HBV patients who have been receiving tenofovir for >6 months with HBV viral load <2000 IU/ml were randomized into two groups...
May 2017: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://www.readbyqxmd.com/read/28611272/a-case-report-of-hepatocellular-carcinoma-5-years-after-hbsag-loss-in-chronic-hepatitis-delta-how-long-surveillance-is-required
#15
Laura Escolà-Vergé, Mar Riveiro-Barciela, Maria Buti
BACKGROUND: Hepatitis delta virus infection occurs as acute co-infection or as superinfection in patients with preexisting chronic hepatitis B. Chronic hepatitis delta leads to more severe disease than chronic hepatitis B, with more rapid progression of fibrosis and increased risk of hepatocelullar carcinoma. CASE REPORT: We report a case of hepatocelullar carcinoma 5 years after spontaneous clearance of Hepatitis B surface antigen in a patient with previous chronic hepatitis delta...
August 1, 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/28598970/seroprevalence-and-clinical-characteristics-of-viral-hepatitis-in-transfusion-dependent-thalassemia-and-hemophilia-patients
#16
Tyng-Yuan Jang, Pei-Chin Lin, Ching-I Huang, Yu-Mei Liao, Ming-Lun Yeh, Yu-Sheng Zeng, Po-Cheng Liang, Wan-Yi Hsu, Shih-Pien Tsai, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Chung-Feng Huang, Shyh-Shin Chiou, Wan-Long Chuang, Ming-Lung Yu
BACKGROUND/AIMS: Transfusion dependent subjects are at a great risk of viral hepatitis infection. We aimed to evaluate the prevalence and factors associated with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection among transfusion-dependent patients in Taiwan. METHODS: A total of 140 patients (67 thalassemic patients, 70 hemophilic patients, two patients with hereditary spherocytosis and one patient with von Willebrand disease) were prospectively enrolled to evaluate the prevalence and factors associated with viral hepatitis and spontaneous HCV clearance...
2017: PloS One
https://www.readbyqxmd.com/read/28521640/antibody-mediated-immunotherapy-against-chronic-hepatitis-b-virus-infection
#17
Ying Gao, Tian-Ying Zhang, Quan Yuan, Ning-Shao Xia
The currently available drugs to treat hepatitis B virus (HBV) infection include interferons and nucleos(t)ide analogs, which can only induce disease remission and are inefficient for the functional cure of patients with chronic HBV infection (CHB). Since high titers of circulating hepatitis B surface antigen (HBsAg) may be essential to exhaust the host anti-HBV immune response and they cannot be significantly reduced by current drugs, new antiviral strategies aiming to suppress serum hepatitis B surface antigen (HBsAg) could help restore virus-specific immune responses and promote the eradication of the virus...
August 3, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28521532/new-antivirals-for-the-treatment-of-chronic-hepatitis-b
#18
REVIEW
Vincent Soriano, Pablo Barreiro, Laura Benitez, Jose M Peña, Carmen de Mendoza
Current treatment with oral nucleos(t)ides entecavir or tenofovir provide sustained suppression of HBV replication and clinical benefit in most chronic hepatitis B virus (HBV) infected persons. However, HBV rebound generally occurs upon drug discontinuation due to persistence of genomic HBV reservoirs as episomic cccDNA and chromosomic integrated HBV-DNA. There is renewed enthusiasm on HBV drug discovery following recent successes with antivirals for hepatitis C and immunotherapies for some cancers. Areas covered: New drugs that target distinct steps of the HBV life cycle are been developed, including inhibitors of viral entry, new polymerase inhibitors, capsid and assembly inhibitors, virus release blockers, and disruptors of cccDNA formation and transcription...
July 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28450703/changes-in-the-prevalence-of-hbsag-and-hbeag-a-study-of-8696-parturients-in-a-well-vaccinated-area
#19
Chen-Hsuan Wu, Te-Yao Hsu, Fu-Tsai Kung, Chan-Chao ChangChien, Ching-Chang Tsai, Sheng-Nan Lu
To elucidate the impact of a hepatitis B (HB) vaccination program on the prevalence of HB surface antigen (HBsAg) and HB envelope antigen (HBeAg) as well as the success rate of HBeAg clearance among parturients, we collected data on parturients who gave birth between 2000 and 2010, and recorded the HB status postpartum of those with positive HBeAg before birth. A total of 8696 parturients were enrolled, of whom 113 with prenatal positive HBeAg were invited back. The prevalence of HBsAg decreased over the study period, particularly in the vaccinated cohort, while there was no change in the prevalence of HBeAg...
April 27, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28445927/vaccines-targeting-pres1-domain-overcome-immune-tolerance-in-hepatitis-b-virus-carrier-mice
#20
Yingjie Bian, Zheng Zhang, Zhichen Sun, Juanjuan Zhao, Danming Zhu, Yang Wang, Sherry Fu, Jingya Guo, Longchao Liu, Lishan Su, Fu-Sheng Wang, Yang-Xin Fu, Hua Peng
Strong tolerance to hepatitis B virus (HBV) surface antigens limits the therapeutic effect of the conventional hepatitis B surface antigen (HBsAg) vaccination in both preclinical animal models and patients with chronic hepatitis B (CHB) infection. In contrast, we observed that clinical CHB patients presented less immune tolerance to the preS1 domain of HBV large surface antigen. To study whether targeting the weak tolerance of the preS1 region could improve therapy gain, we explored vaccination with the long peptide of preS1 domain for HBV virions clearance...
October 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
keyword
keyword
42773
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"